NR1H2 and glioblastoma: A recent study has shown that the liver X receptor (LXR) agonist LXR-623 is selectively effective against GBM cells in an LXR-β and cholesterol-dependent manner, engendering tumor regression and prolonged survival in patient-derived GBM xenograft mouse models [50].